INTS (Intensity Therapeutics) Other Current Liabilities: $0.92 Mil (As of Mar. 2026)


INTS Intensity Therapeutics Inc INTS
28 GF Score
Price $4.52
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics Other Current Liabilities?

Intensity Therapeutics INTS +6.60% 28 Other Current Liabilities is $0.92 Mil as of Mar. 2026. GuruFocus rates INTS with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Intensity Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.92 Mil.

Intensity Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.80 Mil) and increased from Dec. 2025 ($0.80 Mil) to Mar. 2026 ($0.92 Mil).

Intensity Therapeutics's annual other current liabilities declined from Dec. 2023 ($0.39 Mil) to Dec. 2024 ($0.06 Mil) but then increased from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.80 Mil).

Intensity Therapeutics Other Current Liabilities Related Terms

Intensity Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Intensity Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intensity Therapeutics Other Current Liabilities Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.39 0.06 0.80

Intensity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.04 0.01 0.80 0.92
INTS
28GF Score
Intensity Therapeutics Inc INTS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.92 Mil mean?
Intensity Therapeutics (INTS) has a Other Current Liabilities of $0.92 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Intensity Therapeutics.
Is Intensity Therapeutics' Other Current Liabilities too high?
Intensity Therapeutics' current Other Current Liabilities is $0.92 Mil. Overall, Intensity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' Other Current Liabilities compare to KPRX and PHIO?
Intensity Therapeutics' Other Current Liabilities of $0.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Intensity Therapeutics. Intensity Therapeutics's current Other Current Liabilities is $0.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current Other Current Liabilities of $0.92 Mil. The current Other Current Liabilities is $0.92 Mil. Intensity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current Other Current Liabilities is $0.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score

Get the complete analysis for INTS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.52
Price